Combination therapy does not reduce progression of familial adenomatous polyposis

For patients with familial adenomatous polyposis, incidence of disease progression was not significantly lower with combination eflornithine and sulindac compared with either drug alone, according to recently published results.“Additional studies that focus on clinical end points in the lower gastrointestinal tract are warranted to better understand the potential of this combination therapy for pharmacologic prevention in specific groups of patients with familial adenomatous polyposis, especially those who have not yet undergone prophylactic colectomy,” Carol A. Burke, MD, FACG,Read More

Share on facebook
Share on twitter
Share on linkedin